Plain-English translation of NCT05730283 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can prevent or reduce hearing loss caused by amikacin, an antibiotic used to treat serious lung infections. About 105 people will participate across five medical centers. Some participants will receive the medication at a higher dose, some at a lower dose, and others will receive a placebo (a pill with no active medicine) to see how well the treatment works.
Amikacin is an effective antibiotic for treating certain stubborn lung infections, but it can damage the inner ear and cause permanent hearing loss or balance problems. This medication is being developed to protect your hearing while you receive the antibiotic you need.
You likely qualify if…
You likely don't qualify if…
You will take a daily capsule for up to 90 days while you receive your antibiotic treatment—starting with one loading dose, then daily doses afterward. You'll be randomly assigned to receive either the higher-dose medication, the lower-dose medication, or a placebo (neither you nor the researchers will know which you're taking). Throughout the study, your hearing and balance will be tested to see whether the medication helps protect you from hearing loss.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
United States